Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Endo boosts portfolio with branded and generics deal
June 2015
SHARING OPTIONS:

DUBLIN—Endo International plc has acquired a broad portfolio of branded and generic injectable and established products from a subsidiary of Aspen Holdings. The product portfolio covers pain, anti-infectives, cardiovascular and other specialty therapeutic areas, and generated approximately $28 million in revenue in the fiscal year ended June 30, 2014; following the close of the deal, it will be integrated into Endo’s Litha Healthcare Group portfolio. Per the terms of the agreement, Endo will pay Aspen Holdings a one-time payment of roughly $130 million. The company expects the transaction to close in Q3 2015 and to be immediately accretive to earnings.
 
“With the acquisition of these products from Aspen Holdings, Endo continues to grow, diversify and optimize its international portfolio and, specifically, further expand its reach into hospital and pharmacy markets in South Africa,” noted Rajiv De Silva, president and CEO of Endo.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.